title: Approach to the patient with advanced differentiated thyroid cancer.
abstract: Patients with advanced thyroid cancer may benefit from l-thyroxine treatment at doses that suppress serum TSH level, local treatment interventions, and radioiodine therapy. In those patients who are refractory to radioiodine therapy and in whom progressive disease has been documented, the efficacy of cytotoxic chemotherapy is poor. Encouraging results have been obtained with the use of kinase inhibitors that should be offered as first-line treatment, preferably in the context of a prospective trial.
authors: Department of Nuclear Medicine and Endocrine Oncology, Centre de Référence Tumeurs Réfractaires de la Thyroïde, Institut Gustave Roussy and University Paris-Sud XI, 94800 Villejuif, France. schlumbg@igr.fr
authors: M
authors: M
authors: Schlumberger
authors: S I
authors: SI
authors: Sherman
mesh_terms: D002986:Clinical Trials as Topic; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D013974:Thyroxine / Q000627:therapeutic use
chemical_list: D007457:Iodine Radioisotopes; D013974:Thyroxine